BioAge Labs (BIOA) had its price target raised by Citigroup Inc. from $15.00 to $52.00. They now have a "buy" rating on the stock.
BioAge Labs Touts Oral NLRP3 Inhibitor BGE-102 Data, Eyes CV Study and Retinal Expansion [Yahoo! Finance]
BioAge Labs (BIOA) is now covered by Oppenheimer Holdings, Inc.. They set an "outperform" rating and a $60.00 price target on the stock.
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference [Yahoo! Finance]
BioAge Labs to Present at Oppenheimer 36th Annual Healthcare Life Sciences Conference